Literature DB >> 21715655

IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.

Qian Zhang1, Hong Yi Wang, Xiaobin Liu, Gauri Bhutani, Kanchan Kantekure, Mariusz Wasik.   

Abstract

Anaplastic lymphoma kinase (ALK), physiologically expressed only by certain neural cells, becomes highly oncogenic, when aberrantly expressed in nonneural tissues as a fusion protein with nucleophosphin (NPM) and other partners. The reason why NPM-ALK succeeds in transforming specifically CD4(+) T lymphocytes remains unknown. The IL-2R common γ-chain (IL-2Rγ) is shared by receptors for several cytokines that play key roles in the maturation and growth of normal CD4(+) T lymphocytes and other immune cells. We show that IL-2Rγ expression is inhibited in T-cell lymphoma cells expressing NPM-ALK kinase as a result of DNA methylation of the IL-2Rγ gene promoter. IL-2Rγ promoter methylation is induced in malignant T cells by NPM-ALK. NPM-ALK acts through STAT3, a transcription factor that binds to the IL-2Rγ gene promoter and enhances binding of DNA methyltransferases (DNMTs) to the promoter. In addition, STAT3 suppresses expression of miR-21, which selectively inhibits DNMT1 mRNA expression. Reconstitution of IL-2Rγ expression leads to loss of the NPM-ALK protein and, consequently, apoptotic cell death of the lymphoma cells. These results demonstrate that the oncogenic tyrosine kinase NPM-ALK induces epigenetic silencing of the IL-2Rγ gene and that IL-2Rγ acts as a tumor suppressor by reciprocally inhibiting expression of NPM-ALK.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715655      PMCID: PMC3141982          DOI: 10.1073/pnas.1100319108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.

Authors:  Qian Zhang; Puthryaveett N Raghunath; Liquan Xue; Miroslaw Majewski; David F Carpentieri; Niels Odum; Stephan Morris; Tomasz Skorski; Mariusz A Wasik
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

Review 2.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

3.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.

Authors:  D Bischof; K Pulford; D Y Mason; S W Morris
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

Review 4.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

5.  MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

Authors:  Ramiro Garzon; Shujun Liu; Muller Fabbri; Zhongfa Liu; Catherine E A Heaphy; Elisa Callegari; Sebastian Schwind; Jiuxia Pang; Jianhua Yu; Natarajan Muthusamy; Violaine Havelange; Stefano Volinia; William Blum; Laura J Rush; Danilo Perrotti; Michael Andreeff; Clara D Bloomfield; John C Byrd; Kenneth Chan; Lai-Chu Wu; Carlo M Croce; Guido Marcucci
Journal:  Blood       Date:  2009-02-11       Impact factor: 22.113

6.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

Review 7.  Epigenetic opportunities and challenges in cancer.

Authors:  Jonathan D Best; Nessa Carey
Journal:  Drug Discov Today       Date:  2009-11-06       Impact factor: 7.851

8.  Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain.

Authors:  J P DiSanto; W Müller; D Guy-Grand; A Fischer; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

9.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).

Authors:  J Fujimoto; M Shiota; T Iwahara; N Seki; H Satoh; S Mori; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Determination of quantitative and site-specific DNA methylation of perforin by pyrosequencing.

Authors:  Supraja Narasimhan; Virginia R Falkenberg; Maung M Khin; Mangalathu S Rajeevan
Journal:  BMC Res Notes       Date:  2009-06-12
View more
  24 in total

Review 1.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

2.  NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma.

Authors:  E Pomari; G Basso; S Bresolin; M Pillon; E Carraro; E S d'Amore; G Viola; C Frasson; K Basso; P Bonvini; L Mussolin
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

3.  Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation.

Authors:  Heehyoung Lee; Peng Zhang; Andreas Herrmann; Chunmei Yang; Hong Xin; Zhenghe Wang; Dave S B Hoon; Stephen J Forman; Richard Jove; Arthur D Riggs; Hua Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

4.  IL-2/IL-2R signaling and IL-2Rα-targeted therapy in anaplastic large cell lymphoma.

Authors:  Huan-Chang Liang
Journal:  Pathologie (Heidelb)       Date:  2022-09-12

5.  Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Authors:  Michal Marzec; Krzysztof Halasa; Xiaobin Liu; Hong Y Wang; Mangeng Cheng; Donald Baldwin; John W Tobias; Stephen J Schuster; Anders Woetmann; Qian Zhang; Suzanne D Turner; Niels Ødum; Mariusz A Wasik
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

6.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

7.  STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.

Authors:  Katharina L Kopp; Ulrik Ralfkiaer; Lise Mette R Gjerdrum; Rikke Helvad; Ida H Pedersen; Thomas Litman; Lars Jønson; Peter H Hagedorn; Thorbjørn Krejsgaard; Robert Gniadecki; Charlotte M Bonefeld; Lone Skov; Carsten Geisler; Mariusz A Wasik; Elisabeth Ralfkiaer; Niels Ødum; Anders Woetmann
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534

8.  Regulatory T cell microRNA expression changes in children with acute Kawasaki disease.

Authors:  F-F Ni; C-R Li; Q Li; Y Xia; G-B Wang; J Yang
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

Review 9.  Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.

Authors:  Melanie R Hassler; Aleksandra Klisaroska; Karoline Kollmann; Irene Steiner; Martin Bilban; Ana-Iris Schiefer; Veronika Sexl; Gerda Egger
Journal:  Biochimie       Date:  2012-06-09       Impact factor: 4.079

10.  NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.

Authors:  Joel D Pearson; Jason K H Lee; Julinor T C Bacani; Raymond Lai; Robert J Ingham
Journal:  J Signal Transduct       Date:  2012-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.